Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
1 hedge funds and large institutions have $0 invested in Sienna Biopharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less capital invested
Capital invested by funds: $2.07K → $0 (-$2.07K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PO
Private Ocean
San Rafael,
California
|
-$1K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$72 |
SNNA Hedge Fund Activity: Q1 2020 in Review
1 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q1 2020, worth a combined $0 — down 100% from $2.07K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SNNA and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Private Ocean, exiting entirely with an estimated $1K sold.
- 1 institutional investor held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q1 2020, down from 4 in Q4 2019.
- Funds reported $0 of Sienna Biopharmaceuticals, Inc. stock for Q1 2020, down 100% quarter-over-quarter.
- 0 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q1 2020 and 3 closed out, a net change of -3 holders.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q1 2020 was Private Ocean, an estimated $1K sold.
Based on aggregated 13F filings for Q1 2020.